Entecavir and lamivudine therapy for severe acute chronic hepatitis B

Liu, Changhong; Ye, Jing; Jia, Hongyu; Zhang, Meijuan; Han, Hongfeng; Chen, Fengzhe; Chen, Congkang

doi:10.3892/etm.2012.850

Cited by 11 publications

(7 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This finding needs further confirmation. However, other studies have found comparable efficacy of entecavir and lamivudine in the short term [ 329 , 343 , 344 ], and long term [ 345 ], or better long-term (52 weeks) survival but not short-term survival as compared to lamivudine [ 346 ]. One meta analysis found that there was no significant difference in the prognosis of patients treated with entecavir or lamivudine [36.4 vs. 40.5 %, RR 0.77, 95 % CI (0.45, 1.32), p = 0.35] [ 339 ].…”

Section: Guidelinesmentioning

confidence: 99%

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

et al. 2015

View full text Add to dashboard Cite

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous APASL guidelines for management of HBV infection were published in 2012. The objective of this manuscript is to update the recommendations for the optimal management of chronic HBV infection. The 2015 guidelines were developed by a panel of Asian experts chosen by the APASL. The clinical practice guidelines are based on evidence from existing publications or, if evidence was unavailable, on the experts’ personal experience and opinion after deliberations. Manuscripts and abstracts of important meetings published through January 2015 have been evaluated. This guideline covers the full spectrum of care of patients infected with hepatitis B, including new terminology, natural history, screening, vaccination, counseling, diagnosis, assessment of the stage of liver disease, the indications, timing, choice and duration of single or combination of antiviral drugs, screening for HCC, management in special situations like childhood, pregnancy, coinfections, renal impairment and pre- and post-liver transplant, and policy guidelines. However, areas of uncertainty still exist, and clinicians, patients, and public health authorities must therefore continue to make choices on the basis of the evolving evidence. The final clinical practice guidelines and recommendations are presented here, along with the relevant background information.

show abstract

Section: Guidelinesmentioning

confidence: 99%

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Extended use of lamivudine may lead to resistance, therefore new antivirals like adefovir or tenofovir should be examined for their lower resistance rate and for a longer antiviral therapy [13][14][15]. The findings of a recent study by Changhong Liu et al show that the treatment of chronic hepatitis with entecavir is as safe as lamivudine, however, entecavir is able to inhibit HBV replication, decreases the HBV DNA faster and efficiently, in our case being crucial to begin chemotherapy as soon as possible [16].…”

Section: Discussionmentioning

confidence: 81%

Non-Hodgkin lymphoma as primary bone tumor in a patient with B hepatic viral infection - case report

Ene

Panti

Pleniceanu

et al. 2018

Romanian Journal of Orthopaedic Surgery and Traumatology

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphomas, which has shown an increasing incidence in the past decades. 7% of primary bone tumors consist of non-Hodgkin lymphomas. The etiology of this type of lymphoma is still unclear. Our aim was to study the latest research papers; to highlight the importance of cooperation between different medical specialty departments, in rare cases like NHL as PBT with associated HBV infection.Case report: We present the case of a 39-year-old male patient, who presented to the orthopedic department of the University Emergency Hospital of Bucharest, with moderate pain, swelling, and a palpable mass of the right lower limb.Management and Outcome: The patient underwent several investigations, whose result was DLBCL and an associated HBV infection. Due to the aggressive form of DLBCL, chemotherapeutical treatment has to be initiated as soon as possible to prevent further growth of the tumor. An antiviral therapy had to be initiated to prevent the hepatic failure, which could appear after chemotherapy and in the acute phase of viral infection.Discussion: Our case raised the question regarding what kind of relationship could be identified between the HBV infection and NHL, and how this condition influenced the outcome of the treatment.

show abstract

“…Our results here support the possibility that lamivudine undergoes biotransformation in the liver for clearance, particularly in those having severely advanced hepatitis. This idea is strengthened by the finding that lamivudine, which requires a larger dosing amount than other antiviral agents, may have the potential to cause drug-induced liver injury ( 22 ). In this study, we paid attention to patients suffering from severely advanced hepatitis and diminished liver function, considering this possibility.…”

Section: Discussionmentioning

confidence: 99%

Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis

Choi

Lee

et al. 2017

ToxicolRes

View full text Add to dashboard Cite

Lamivudine belongs to the set of antiviral agents effective against hepatitis B virus infection. Given case reports on liver injuries after certain antiviral agent treatments, this study examined the effects of lamivudine on alanine aminotransferase (ALT) and total bilirubin (TB) using a medical system database. A total of 1,321 patients taking lamivudine alone or with others were evaluated using laboratory hits in an electronic medical system at Seoul National University Hospital from 2005 through 2011. The patients were grouped according to prior ALT results: G#1, ALT < 40 IU/L; G#2, 40 IU/L ≤ ALT < 120 IU/L; G#3, 120 IU/L ≤ ALT < 240 IU/L; and G#4, ALT ≥ 240 IU/L. In G#1 and G#2 patients, lamivudine or adefovir treatment decreased ALT and TB compared to prior values. In G#3 and G#4 patients with three times the upper limit of normal (ULN) ≤ ALT < 15 times the ULN, both ALT and TB were decreased after treatment with lamivudine alone, or adefovir following lamivudine therapy, indicating that lamivudine therapy ameliorated liver functions. However, in G#4 patients who experienced severely advanced hepatitis (ALT ≥ 15 times the ULN, or ≥ 600 IU/L), lamivudine augmented TBmax (6.3→13.3 mg/dL) despite a slight improvement in ALT (839→783 IU/L), indicative of exacerbation of bilirubinemia. Patients who used adefovir after lamivudine also showed a high incidence of hyperbilirubinemia when they experienced severely advanced hepatitis. Treatment with adefovir alone did not show the effect. In conclusion, lamivudine may increase the risk of hyperbilirubinemia in patients with severely advanced hepatitis, implying that caution should be exercised when using lamivudine therapy in certain patient populations.

show abstract

Entecavir and lamivudine therapy for severe acute chronic hepatitis B

Cited by 11 publications

References 19 publications

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update

Non-Hodgkin lymphoma as primary bone tumor in a patient with B hepatic viral infection - case report

Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis

Contact Info

Product

Resources

About